Group 1 - The company reported a revenue of 39.57 million yuan for Q1 2025, representing a year-on-year increase of 30.01% [1] - The net profit attributable to shareholders was -5.94 million yuan, an improvement from -8.25 million yuan in the same period last year [1] - The net cash flow from operating activities was -9.83 million yuan, compared to -28.37 million yuan in the previous year [1] Group 2 - In 2024, the company achieved a revenue of 218 million yuan, a decline of 37.97% year-on-year [1] - The net profit attributable to shareholders for 2024 was -26.49 million yuan, down from a profit of 45.52 million yuan the previous year [1] - The company went public on May 26, 2023, with an initial stock price of 32.60 yuan per share, and is currently trading below its initial offering price [1] Group 3 - The total amount raised from the initial public offering was 849.23 million yuan, with a net amount of 765.76 million yuan after deducting issuance costs [2] - The final net amount raised exceeded the original plan by 446.91 million yuan [2] - The company plans to use the raised funds for upgrading its smart medical information platform, building a research center, developing a marketing network, and supplementing working capital [2]